A new phase I clinical trial conducted at the University of Minnesota Medical School indicates that gene therapy treatment may prevent the recurrence of brain cancer cancer. The trial, conducted on 56 patients with recurrent high-grade glioma brain cancer shows that "3 years after the gene therapy treatment, more than a quarter of the patients were still alive." Median survival time for patients was raised to 14.4 months, compared to 8 months for patients without the gene therapy.
Click here to read more about this trial, results of which were presented on Friday, October 27th at the International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia.
No comments:
Post a Comment